Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21222354 | 0.86 | BTK (0.47) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL21228026 | 0.83 | BTK (0.46) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL18616097 | 0.83 | BTK (0.46) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL19358642 | 0.83 | BTK (0.46) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL14669045 | 0.83 | BTK (0.49) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL24751681 | 0.82 | BTK (0.45) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL15845050 | 0.82 | BTK (0.45) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL18624574 | 0.81 | BTK (0.46) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL668997 | 0.81 | BTK (0.73) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL668998 | 0.81 | BTK (0.73) | BTKCTSKGAAKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| CN-115843295-B | NAMPT modulators | 赛特凯恩蒂克公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119487006-A | Amide compounds as PGE2 receptor antagonists | 广东新契生物医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4384493-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2024-06-19 | — | — | EP | disclosed |
| CN-118076581-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118047800-A | Dual-function chimeric heterocyclic compound of interleukin-1 receptor related kinase, and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-117157298-A | Dual-function chimeric heterocyclic compound of interleukin-1 receptor related kinase 4, preparation method, medicinal composition and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2023186069-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-10-05 | — | — | WO | disclosed |
| EP-2729458-B1 | PROCESSES FOR THE PREPARATION OF THIETANAMINE | SYNGENTA PARTICIPATIONS AG (CH) | 2016-10-05 | — | — | EP | disclosed |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| WO-2016010950-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016010950-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-21 | — | — | WO | disclosed |
| US-9006456-B2 | Processes for the preparation of thietanamine | SYNGENTA PARTICIPATIONS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| US-20140187788-A1 | PROCESSES FOR THE PREPARATION OF THIETANAMINE | SYNGENTA PARTICIPATIONS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| EP-2729458-A2 | PROCESSES FOR THE PREPARATION OF THIETANAMINE | Syngenta Participations AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013007582-A2 | PROCESSES FOR THE PREPARATION OF THIETANAMINE | SYNGENTA PARTICIPATIONS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187788-A1 | PROCESSES FOR THE PREPARATION OF THIETANAMINE | INMT, HNMT, TST | BTK 2227/4885CYP2C19 125/4885CTSK 2325/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | BTK 4182/4885CYP2C19 1361/4885CTSK 4012/4885 |
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR1I3, NR1H4 | BTK 1925/4885CYP2C19 181/4885CTSK 4154/4885 |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | BTK 415/4885CYP2C19 1158/4885CTSK 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.